American biochemist to receive this year's Inhoffen Medal
HZI
The prize, which is funded by the Friends of the Helmholtz Centre for Infection Research (HZI), is awarded on the occasion of the public Inhoffen Lecture, an event co-hosted by the HZI and the Technische Universität (TU) Braunschweig. This year, the Inhoffen Lecture is scheduled for 3 pm on Thursday, 25 April, and will be given in the HZI forum. "The award is bestowed in recognition of Walsh's impressive contribution to science," explains Prof. Dietmar Schomburg, Chairman of the Friends of the HZI.
Bacteria use clever "assembly lines" to make active substances they need to survive. Many of these substances are of medical interest for us humans as they can be used as antibiotics, for example. Christopher T. Walsh, professor at the renowned Harvard Medical School in Boston, USA, is a leading expert in the area of bacterial "factories".
Much of his research has been concerned with the investigation of the structure and function of enzymes, cellular catalysts, to better understand their molecular basis. Among other things, Walsh studied substances known as suicide inhibitors - compounds that, normally, are recognized and converted by some enzyme catalyst. The enzyme mistakes them for natural reaction partners, binds and converts them - leading to production of an inhibitory substance that acts to permanently block the enzyme. Suicide inhibitors that are effective against bacterial enzymes can be continually developed for application in medicine.
Walsh's work also allowed for artificially changing bacterial enzymes. This represents a major step forward for active substance biosynthesis. He also discovered how bacteria evolve resistance to the reserve antibiotic vancomycin - a discovery which helped move production of new antibiotics forward.
Most read news
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.